DBV Technologies (DBVT) Accumulated Depreciation & Amortization (2019 - 2025)
DBV Technologies (DBVT) reported Accumulated Depreciation & Amortization of $3.0 million for Q4 2025, up 10.25% year-over-year from $2.7 million in Q4 2024, and up 10.25% on a QoQ basis from $2.7 million in Q4 2024.
DBV Technologies (DBVT) has 7 years of Accumulated Depreciation & Amortization data on file, last reported at $3.0 million in Q4 2025.
- Quarterly Accumulated Depreciation & Amortization rose 10.25% year-over-year to $3.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.0 million (up 10.25% YoY) and the FY2025 annual result came in at $3.0 million, up 10.25% from the prior year.
- Accumulated Depreciation & Amortization rose to $3.0 million in Q4 2025 per DBVT's latest filing, from $2.7 million in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $14.8 million in Q4 2022 and bottomed at $2.7 million in Q4 2024.
- The 5-year median for Accumulated Depreciation & Amortization is $3.6 million (2023), against an average of $7.6 million.
- The widest annual swing landed in 2023, when Accumulated Depreciation & Amortization plunged 75.66%; it then grew 10.25% in 2025.
- Tracing DBVT's Accumulated Depreciation & Amortization over 5 years: stood at $13.8 million in 2021, then increased by 7.17% to $14.8 million in 2022, then sank by 75.66% to $3.6 million in 2023, then declined by 24.42% to $2.7 million in 2024, then gained by 10.25% to $3.0 million in 2025.
- Per Business Quant, the three latest DBVT Accumulated Depreciation & Amortization figures stand at $3.0 million (Q4 2025), $2.7 million (Q4 2024), and $3.6 million (Q4 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | DBV Technologies | 8.00 Bn | 7.77 Bn | -3.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.00 Mn |
| Dec 31, 2025 | 3.00 Mn |
| Dec 31, 2024 | 2.72 Mn |
| Dec 31, 2024 | 2.72 Mn |
| Dec 31, 2023 | 3.60 Mn |
| Dec 31, 2023 | 3.60 Mn |
| Dec 31, 2022 | 14.79 Mn |
| Dec 31, 2022 | 14.79 Mn |
| Dec 31, 2021 | 13.80 Mn |
| Dec 31, 2021 | 13.80 Mn |
| Dec 31, 2020 | 16.69 Mn |
| Dec 31, 2020 | 16.69 Mn |
| Dec 31, 2019 | 11.47 Mn |
| Dec 31, 2019 | 11.47 Mn |